Rondeau, Jean-Michel
Novartis (Switzerland)
3 papers on CoChatORCID 0000-0003-0575-5480
Most cited papers
- Verified
The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., et al. (2018) · EMBO Molecular Medicine
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 177
- Verified
Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
Morvan, F., Rondeau, J.-M., Zou, C., Minetti, G., Scheufler, C., Scharenberg, M., Jacobi, C., Brebbia, P., Ritter, V., Toussaint, G., et al. (2017) · Proceedings of the National Academy of Sciences
Muscle Physiology and DisordersTGF-β signaling in diseases
Cited by 142
- Verified
Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer’s Disease
Machauer, R., Lueoend, R., Hurth, K., Veenstra, S. J., Rueeger, H., Voegtle, M., Tintelnot-Blomley, M., Rondeau, J.-M., Jacobson, L. H., Laue, G., et al. (2021) · Journal of Medicinal Chemistry
Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases
Cited by 40
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free